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NUMEROUS STUDIES have revealed that
bacterial adjuvants such as BCoG and
BCG cell-wall skeletons have strong anti-
tumour activity for animal tumours and
also for human malignancies (Ogura et al.,
1978; Sarna et al., 1978; Yamamura et al.,
1979). These bacterial adjuvants are pre-
sumed to activate mainly macrophages
and lymphocytes, and render them toxic
to tumour cells (Keller, 1974; Currie &
Basham, 1975; Mansfield & Wallace,
1977). We have reported that the cyto-
static activity of macrophages in tumour-
bearing rats is decreased in the advanced
stage, and that the decreased cytostatic
activity ofmacrophages in tumour-bearing
rats can be restored by local (i.p.) adminis-
tration of BCG (Chikama et al., 1979).
AVe have also investigated the effect of
immunopotentiators in the clinically rele-
vant model of immunochemotherapy for
advanced solid tumours (Saijo et al.,
1979b). In the present study, we first
examined the optimum dose and the
route and schedule of administration of
BCG, focusing our attention on the
systemic effect of BCG. Secondly, we
examined the effect of the anticancer
agent (ACNU) alone or with BCG on the
cytostatic activity of macrophages. We
also analysed the correlation between
this cytostatic activity and the tumour
growth in rats receiving immunochemo-
therapy.
Male Donryni strain rats weighing 120-
Accepte(d 28 Alar.i 19S0
200 g were obtained from Nihon Rat Co.
(Urawa, Japan). These animals had been
inbred for 25 generations and thereafter
bred randomly. The tumour studied was
Sato lung carcinoma (SLC) which had been
maintained by s.c. transplantation in our
laboratory for more than 100 generations.
This tumour was 1000/0 transplantable to
Donryu strain rats and killed the host
within 10-15 or 15-40 days after i.v.
(106 cells) or i.m. (107 cells) transplanta-
tion respectively. The SL( is weakly
immunogenic (Saijo et al., 1978, 1979)
immunized rats rejecting > 107 viable
tumour cells, whilst the minimum inocu-
lum for growth in uinimmunized rats is
104 cells. In the experiments described
here, tumours used as the source of target
cells for cytostatic assay were taken 7 days
after s.c. injection of 107 tumour cells
into normal syngeneic rats. Solid SLC was
dissected free offibrous tissue and cut into
small pieces, which were incubated with
0-25% trypsin for 10 min at 37°C( with
gentle stirring. The cells were collected by
centrifugation (400 q, 10 min) and washed
twice with Hanks' balanced salt solution
(HBSS). The cell suspension contained
about 15% macrophages.
SLC cells (107) suspended in HBSS at a
concentration of 2 x 107/ml were inocu-
lated i.m. into the left thighs of Donryu
strain rats, and the thickness of both
thighs was measured every other day. The
difference in thickness between the leftEFFECTS OF BCGr AND ACNU ON RAT MACROPHAGES
and right thighs was taken as the dia-
meter of the tumour. In the cytostatic
assay, the SLC cell suspension was
adjusted to 106/ml of RPMI 1640 con-
taining 1000 heat-inactivated foetal calf
serum (RPMI-FCS). To remove con-
taminating macrophages, 10 ml of this
SLC suspension was incubated in a
Terumo plastic dish (90 mm in diameter)
(Terumo Co., Tokyo, Japan) in a atmos-
phere of humid 500 CO2 950o air, at 37°C
for 1 h. Non-adherent cells were then
collected by repeated intensive washing
with HBSS. More than 95% of non-
adherent cells were identified as SLC cells
by Giemsa stain.
Living BCG (Nihon BCG Laboratory,
Tokyo, Japan) (1-10 mg) was used as
immunopotentiator. BCG suspended in
physiological saline was injected (i.p. or
i.v.) into Donryu strain rats. Five mg of
BCGC contained 3-4 x 108 living cells.
1 - (4 -amino - 2 -methyl - 5 -pyrimidinyl) -
methyl - 3 - (2 - chloroethyl) - 3 - nitrosourea
hydrochloride (ACNU) (Sankyo Pharma-
ceutical Co.) was dissolved in physio-
logical saline and injected i.v. into normal
and tumour-bearing rats. ACNU, a water
soluble nitrosourea, is effective for animal
tumours and for human malignancies in
large intermittent doses (Saijo & Niitani,
1980).
Peritoneal cells were collected by wash-
ing the peritoneal cavity of Donryu strain
rats with 40 ml ofEagles' MEM containing
heparin 5 u/ml, streptomycin 100 Hg/ml,
penicillin 100 u/ml. The cells were washed
twice with the same solution and finally
suspended in RPMI-FCS at a concentra-
tion of 5 x 105/ml. One-ml quantities of
nucleated-cell suspension were plated in
flat-bottomed glass culture tubes (15 mm
in diameter) and incubated in an atmos-
phere of humid 500 CO2 950o air, at 370C
for 1 h. Each culture was then washed x 3
with PRMI-FCS. The recovery ofadherent
cells in each experimental group ranged
from 41b2-60.8% of plated peritoneal
cells. More than 9500 of these adherent
cells were identified as macrophages on
the basis of cytoplasm and nuclear shape
shown by (Giemsa stain, and by their
phagocytic activity for Indian-ink par-
ticles.
To detect in vivo antitumour activity of
activated peritoneal-exudate cells and
macrophages, the Winn type ofneutraliza-
tion test was performed. Peritoneal cells
were harvested from normal rats and from
rats inoculated i.v. with 5 mg of BCG 21
days before by washing their peritoneal
cavities. They were washed twice with
MEM and finally suspended in RPMI-
FCS at 2 x I06/ml. These cells were
plated in the Terumo plastic dishes, and
incubated for 1 h at 37°C in an atmosphere
of humid 50o CO2 950 air. After non-
adherent cells were removed by repeated
intensive washing with MEM, macro-
phages adhering to the dishes were scraped
with a rubber policeman and washed twice
with RPMI-FCS. They were then sus-
pended in RPMI-FCS and checked for
viability. SLC cells (5 x 104/0-25 ml) and
peritoneal cells or macrophages (5 x 106/
0 25 ml) were mixed and incubated at
37°C for I h. The mixture of these cells
was inoculated i.m. into the left thigh of
normal Donryu strain rats, and the
tumour size was measured every other day.
The cytostatic activity was determined
by the modification of Germain's method
(Germain et al., 1975; Williams et al.,
1975). Flat-bottomed glass tubes (15 mm
in diameter) were used for the cytostatic
assay. SLC cells (2.5 x 105 cells/0 25 ml of
RPMI-FCS) and 0 5 ml of RPMI-FCS
were placed on the monolayer of the
macrophages obtained as described above.
The cytostatic activity of macrophages
from normal rats was the control. The
cells were incubated in 50o CO2, at 37°C
for 3 h, and 0 5 tmCi of 3H-thymidine
(Radiochemical Centre, Amersham, U.K.)
in 0-25 ml of RPMI-FCS was added. After
further incubation for 3 h, the cells were
harvested on a Whatman CGF/C filter
(W and R Balston Co., U.K.) and washed
with 5 ml of 500 cold trichloroacetic acid
x 3 and dried with methanol. The filters
containing the cells were transferred to
glass vials containing toluene-based
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scintillation fluid, and their radioactivity
was counted with a liquid scintillation
counter (Packard, U.S.A.). Under these
conditions, the average radioactivity in
the culture of tumour cells alone or
macrophages alone was 36,788 + 2645 ct/
min, and 887 + 182 ct/min respectively.
The cytostatic activity was expressed as
the percentage of inhibition of DNA
synthesis of SLC cells calculated from the
following formula:
Inhibition of DNA synthesis (00)=
ct/min (effector cell+target
1 _ cell) -ct/min (effector cell) x 100 ct/min (target cell) -
ct/min (medium alone)
The cytostatic activity ofnormal macro-
phages was 44 3, 49.4, 53 0 and 62.0%
when the ratio of macrophages to
SLC cells was 0-5:1, 1:1, 1-5:1 and 2:1
respectively. Based on these data, the
effector to target cell (E:T) ratio of 1:1
was used in all the experiments.
The results in Fig. 1 represent the
effect of i.v. BCG on the number of
peritoneal cells and on the cytostatic
activity of peritoneal macrophages. The
respective values in normal rats were
22-0 + 0-8 x 106 and 49.4 + 2 6%. The
Cytostatic 100 Cyto!
activity A Time course acti
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values gradually increased after i.v. BCG
and reached a maximum level in 21 days
(Fig. IA). The number of peritoneal cells
increased in rats receiving 5 mg or more
of BCG. On the other hand, the cytostatic
activity of peritoneal macrophages in-
creased with each dose, in rats adminis-
tered BCG i.v. from 1-10 mg (Fig.
1B). About 20% of the rats receiving
10 mg of BCG died of toxicity. Based on
these data, it seemed to be reasonable to
give 5 mg of BCG i.v. 21 days before the
experiments in order to obtain the maxi-
mum effect.
To clarify the mechanism of in vitro
cytostatic activity of immunopotentiator-
activated macrophages for SLC cells, a
neutralization test was performed. The
tumour grew progressively in all the 8 rats
or 5/6 rats inoculated i.m. with SLC cells
mixed with normal peritoneal cells or
macrophages, respectively. On the other
hand, we could detect tumour growth in
only 2/8 rats or 1/6 rats receiving SLC
cells mixed with peritoneal exudate cells
or macrophages from rats inoculated i.v.
with BCG, respectively.
The results in Fig. 2 demonstrate the
effect of ACNU alone or ACNU+BCG
on the number of peritoneal cells and the
cytostatic activity of peritoneal macro-
atic 10o
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Fia. 1.-Effect of BCG (i.v.) on the number (0 0) of peritoneal cells and cytostatic activity
(0 0) of peritoneal macrophages. Normal range (mean + s.e.) of cytostatic activity I; normal range (mean+ s.e.) of the number of peritoneal cells
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FIG. 2. Effect of ACNU and BCG on the
number of peritoneal cells (e) and
cytostatic activity (LO) of peritoneal
macrophages. A, normal (56 animals); B,
ACNU (30 mg/kg) administered i.v. 7 days
before measurements ( 11 animals); C, ACNU
(as in B) and BCG (5 mg) administered
i.v. 21 days before measurements (6
animals).
phages in normal rats. The maximum
tolerated dose of ACNU (30 mg/kg) was
selected for this experiment. One week
after the administration of ACNU, the
number of peritoneal cells and the cyto-
static activity of the macrophages de-
creased significantly. The cytostatic acti-
vity was 21P7+4.9% in animals treated
with ACNU, and returned to normal level
2 weeks later. The number of peritoneal
cells and the cytostatic activity of macro-
phages were not decreased in rats receiving
less than 20 mg of ACNU per kg. The
cytostatic activity of macrophages was
increased to 65-1 + 5-1% in rats adminis-
tered both ACNU and BCG.
In order to evaluate the effect of the
anticancer agent, and/or the immuno-
potentiator on the number of peritoneal
cells and the cytostatic activity of macro-
phages, as well as on tumour growth, 107
SLC cells were inoculated i.m. into the
left thigh of Donryu strain rats 21 days
before the assays. ACNU (30 mg/kg) and
BCG (5 mg) were administered i.v. 7 and
21 days before the assays, respectively.
The tumour size in untreated rats was
28-7 + 1-0 mm 21 days after i.m. inocula-
tion. The number of peritoneal cells and
their cytostatic activity were significantly
decreased in this group of tumour-bearing
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FIG. 3. Effect of BCG and/or ACNU on
tumour size, number of peritoneal cells
(f) and cytostatic activity (Lii) of
peritoneal macrophages in tumour-bearing
rats. A, 56 normal rats; B, 7 tumour-
bearing rats (107 SLC cells i.m. 21 days
earlier); C, 6 tumour-bearing rats, BCG
administered i.v. 21 days earlier; D, 7
tumour-bearing rats, ACNU (30 mg/kg)
administered i.v. 7 days earlier; E, 8
tumour-bearing rats, BCG (as in C) and
ACNU (as in D). Tumour size (mm): B,
28-7+1-0; C, 27-7+1-3 (N.S.); D, 23-9+
1-7 (P < 0-05); E, 16-3 + 3-4 (P<002).
rats (Fig. 3). In rats receiving 5 mg i.v.
BCG at the time of tumour inoculation,
the tumour size was 27-7 + 1P3 mm. How-
ever, the number of peritoneal cells and
the cytostatic activity of macrophages
returned to the normal level (Fig. 3). In
rats treated with 30 mg/kg of ACNU i.v.,
the tumour size decreased to 23-9 + 1-0
mm; though the number of peritoneal
cells and the cytostatic activity of macro-
phages remained at low levels (Fig. 3). On
the other hand, in rats treated with the
combination of ACNU and BCG, the
tumour size decreased to 16-3 + 3-4 mm,
and the number of peritoneal cells, and
the cytostatic activity of macrophages,
were 20-8+7-1x 106 and 73-9+7.7/4% re-
spectively (Fig. 3).
The vital role ofmacrophages in control
of tumour growth and dissemination is
well recognized, and many studies have
reported nonspecific activation of macro-
phages by a variety of immunopotenti-
ators, to become inhibitory for tumour
cells in vivo and in vitro (Schultz et al.,
1977). However, there are few available
data on the cytostatic activity of macro-
phages in rats (normal or tumour-bearing)
administered systemically with anticancer
agents and immunopotentiators.
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In an earlierstudy, we detected astrong
cytostatic activity of macrophages in
Donryu strain rats inoculated i.p. with
I mg ofBCG (Chikama et al., 1979). In the
present study, we showed that it was
necessary to give 5 mg or more of BCG by
i.v. administration in order to increase the
cytostatic activity of macrophages, and
that the maximum cytostatic activity
-against SLC cells appeared 3 weeks later.
These results suggest the activation of
peritoneal macrophages by systemic ad-
ministration of BCCx, the effect varying
according to dose, and to the route and
schedule of administration. In the Winn
type of neutralization test, the macro-
phages of normal rats failed to suppress
tumour growth which was strongly sup-
pressed by BCG-activated macrophages.
In other words, the increased cytostatic
activity of macrophages correlated well
with the in vivo suppression of tumour
growth. In our study of the effect of
ACNU on the cytostatic activity of
macrophages in normal rats, we found
that this was decreased in rats receiving
the maximum tolerated dose of ACNU;
but it was easily restored or even elevated
by the combination of ACNU and 5 mg
of i.v. BCG. Thus the decrease in cyto-
static activity ofmacrophages induced by
ACNU can be prevented by the systemic
administration of BCG. The cytostatic
activity of macrophages was significantly
decreased in tumour-bearing rats, but was
restored to the normal level by i.v. BCG,
though the tumour growth was not in-
fluenced by BCG administration. Tumour
growth was significantly suppressed in
animals receiving ACNU. In animals
treated with ACNU and BCG, tumour
growth was more effectively suppressed
than when treated with ACNU alone. The
cytostatic activity of macrophages in
these animals was also apparently higher
than in those treated with BCG or ACNU
alone. Tt is suggested, therefore, that the
systemic administration of BCG can
potentiate the effect of the anticancer
agent, and that raised cytostatic activity
of macrophages contributes to the sup-
pression of tumour growth. There have
been numerous clinical studies on the
effect of immunopotentiators such as
BCG and BCG-CWS on malignant melan-
oma, lung cancer, and leukaemia (Holoye
et al., 1978; Sarna et al., 1978; Yamamura
et al., 1979). However, the positive role of
immunochemotherapy for advanced solid
tumours is still under discussion. Hoso-
kawa et al. (1971) reported that the
optimal dose, route and timing of im-
munopotentiators have a very limited
range. In our study the dose, route and
timing of BCG administration were deter-
mined from the cytostatic activity of
macrophages which inhibited theregrowth
of tumours treated by chemotherapy. In
conclusion, it is argued that the preferred
administration of immunopotentiators
should be determined from the analysis of
nonspecific and specific immune responses,
such as macrophage-mediated cytostatic
and cytolytic activity, natural killer
activity (Saijo et al., 1980) and antibody-
dependent cellular cytotoxicity, as well as
specific cytotoxicity of T-cell and mixed
lymphocyte target interaction, which are
directed at the tumour itself.
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